Instituto de Parasitología y Biomedicina Lopez-Neyra, CSIC, Parque Tecnológico de Ciencias de la Salud, Avenida del Conocimiento s/n Armilla, Granada-18100, Spain.
Arthritis Res Ther. 2010;12(2):R51. doi: 10.1186/ar2962. Epub 2010 Mar 23.
The objective was to investigate the potential implication of the IL18 gene promoter polymorphisms in the susceptibility to giant-cell arteritis (GCA).
In total, 212 patients diagnosed with biopsy-proven GCA were included in this study. DNA from patients and matched controls was obtained from peripheral blood. Samples were genotyped for the IL18-137 G>C (rs187238), the IL18-607 C>A (rs1946518), and the IL18-1297 T>C (rs360719) gene polymorphisms with polymerase chain reaction, by using a predesigned TaqMan allele discrimination assay.
No significant association between the IL18-137 G>C polymorphism and GCA was found. However, the IL18 -607 allele A was significantly increased in GCA patients compared with controls (47.8% versus 40.9% in patients and controls respectively; P = 0.02; OR, 1.32; 95% CI, 1.04 to 1.69). It was due to an increased frequency of homozygosity for the IL18 -607 A/A genotype in patients with GCA (20.4%) compared with controls (13.4%) (IL18 -607 A/A versus IL18 -607 A/C plus IL18 -607 C/C genotypes: P = 0.04; OR, 1.59; 95% CI, 1.02 to 2.46). Also, the IL18-1297 allele C was significantly increased in GCA patients (30.7%) compared with controls (23.0%) (P = 0.003; OR, 1.48; 95% CI, 1.13 to 1.95). In this regard, an increased susceptibility to GCA was observed in individuals carrying the IL18-1297 C/C or the IL18-1297 C/T genotypes compared with those carrying the IL18-1297 T/T genotype (IL18-1297 C/C plus IL18-1297 T/C versus IL18-1297 T/T genotype in GCA patients compared with controls: P = 0.005; OR, 1.61; 95% CI, 1.15 to 2.25). We also found an additive effect of the IL18 -1297 and -607 polymorphisms with TLR4 Asp299Gly polymorphism. The OR for GCA was 1.95 for combinations of genotypes with one or two risk alleles, whereas carriers of three or more risk alleles have an OR of 3.7.
Our results show for the first time an implication of IL18 gene-promoter polymorphisms in the susceptibility to biopsy-proven GCA. In addition, an additive effect between the associated IL18 and TLR4 genetic variants was observed.
本研究旨在探讨白细胞介素 18(IL18)基因启动子多态性与巨细胞动脉炎(GCA)易感性的潜在关联。
本研究共纳入 212 例经活检证实的 GCA 患者。从患者和匹配对照的外周血中提取 DNA。采用聚合酶链反应(PCR),使用预设计的 TaqMan 等位基因鉴别检测法,对 IL18-137 G>C(rs187238)、IL18-607 C>A(rs1946518)和 IL18-1297 T>C(rs360719)基因多态性进行基因分型。
未发现 IL18-137 G>C 多态性与 GCA 之间存在显著关联。然而,与对照组相比,GCA 患者的 IL18-607 等位基因 A 明显增加(分别为 47.8%和 40.9%;P=0.02;OR,1.32;95%CI,1.04 至 1.69)。这归因于 GCA 患者 IL18-607 A/A 基因型的纯合子频率增加(20.4%),而对照组为 13.4%(IL18-607 A/A 与 IL18-607 A/C 加 IL18-607 C/C 基因型:P=0.04;OR,1.59;95%CI,1.02 至 2.46)。此外,与对照组相比,GCA 患者的 IL18-1297 等位基因 C 明显增加(30.7%与 23.0%;P=0.003;OR,1.48;95%CI,1.13 至 1.95)。在这方面,与携带 IL18-1297 T/T 基因型的个体相比,携带 IL18-1297 C/C 或 IL18-1297 C/T 基因型的个体对 GCA 的易感性增加(GCA 患者中 IL18-1297 C/C 加 IL18-1297 T/C 与 IL18-1297 T/T 基因型相比:P=0.005;OR,1.61;95%CI,1.15 至 2.25)。我们还发现 IL18-1297 和-607 多态性与 TLR4 Asp299Gly 多态性之间存在累加效应。携带一个或两个风险等位基因的 GCA 组合的 OR 为 1.95,而携带三个或更多风险等位基因的携带者的 OR 为 3.7。
我们的研究结果首次表明白细胞介素 18 基因启动子多态性与活检证实的 GCA 易感性有关。此外,还观察到相关的 IL18 和 TLR4 遗传变异之间存在累加效应。